Mounjaro® (tirzepatide)

Disclaimer: This article was published in 2023 and reflects the information available at that time.

In recent weeks, the PDL Professional Officers have received a number of queries regarding pharmacists’ obligations and liability when dispensing Mounjaro® (tirzepatide). Tirzepatide is a long-acting dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It is registered with the TGA and indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise, as monotherapy when metformin is not tolerated or contraindicated, or in addition to other medicinal products for the tr…